Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,542.42 26.15 0.18%
TOPIX 1,172.80 -0.57 -0.05%
HANG SENG 22,760.24 64.23 0.28%

Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid



  Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor
  Baricitinib Advances into Phase III Development for Rheumatoid Arthritis

Business Wire

WILMINGTON, Del. -- November 15, 2012

Incyte Corporation (NASDAQ: INCY) announced today that it has earned a $50
million milestone payment from Eli Lilly and Company based on the formal
initiation of the rheumatoid arthritis (RA) Phase III program for baricitinib,
Incyte’s oral JAK1/JAK2 inhibitor, formerly known as INCB28050. The Phase III
program is being conducted by Lilly as part of the exclusive worldwide
License, Development and Commercialization Agreement for baricitinib

About the Phase III Program

Four Phase III RA studies are planned, which will investigate the safety and
efficacy of baricitinib 2 mg and 4 mg once daily in patients with active RA
who are methotrexate-naive, biologic-naive or biologic-experienced. Patients
completing any of the four studies will be eligible for enrollment in a fifth
study, a long-term extension. Information about the clinical trials can be
viewed at www.clinicaltrials.gov.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company
focused on the discovery, development and commercialization of proprietary
small molecule drugs for oncology and inflammation. For additional information
on Incyte, please visit the Company’s website at www.incyte.com.

Forward-Looking Statement

Except for the historical information set forth herein, the matters set forth
in this press release, including the statement with respect to the Phase III
program being expected to include four Phase III studies, contain predictions,
estimates and other forward-looking statements. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including the high degree of risk and
uncertainty associated with drug development and clinical trials, the ability
to enroll a sufficient number of patients, and other risks detailed from time
to time in Incyte's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended Sept. 30,
2012. Incyte disclaims any intent or obligation to update these
forward-looking statements.

Links to third-party websites or pages are provided for convenience only. Each
website is subject to its own terms of use, and we encourage you to consult
these policy statements. Incyte has no control over third party sites and does
not endorse or recommend these sites, and expressly disclaims any
responsibility for the accuracy of content or opinions set forth in any third
party website or your use of that information.

Contact:

Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations/Corporate Communications
302/498-6944
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement